EN DE

UV Germi SA (ALUVI) Fair Value & Analysis

Industrials · FR · Market cap €6.0M

UG UV Germi SA ALUVI · PA
Price€2.70
Fair Value€0.8800
Upside-67.4%
Quality64/100
Watch UV Germi SA for free, get notified when fair value or trend changes. Watch for free
Weak Growth
Thin margins · 1.4% net margin
Low debt · generates free cash flow
Mixed vs. peers (6/13)
Narrow moat 25/100
Evidence: High Range €0.6600 – €1.11 Share as image

Fair value as of: Jul 20, 2026

From 22 valuation models · updated 21 days ago

Share price +10.7% over the past month.

A solid business, but screening 67% overvalued on our models.

What matters now

  • The price sits above even our optimistic bull case (€1.11). The favourable scenario is already priced in.
  • Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

€10.14 €1.93 Fair Value €0.8800 Jun 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 20, 2026.

How to read this chart

60‑month range €1.93 – €10.14 · fair‑value band €0.6600 – €1.11 · the €2.70 price screens above the €0.8800 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 20, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

UV Germi SA (ALUVI) currently trades at €2.70, while our model-based Fair Value estimate is €0.8800, implying the stock looks roughly 67.4% overvalued today. The Quality Score stands at 64/100 (solid quality), in the Industrials sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, UV Germi SA generated revenue of €7.0M at a net margin of 1.4%. Revenue grew 7.4% year over year. It earns a return on equity of 1.0%. The balance sheet holds a net cash position of €4.1M. Fundamentals as of Jul 20, 2026

Our scenario range runs from €0.6600 (bear case) to €1.11 (bull case); at €2.70, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 25% below its 52-week high and 44% above its 52-week low, currently above its 200-day average. For context, the median of 10 Industrials peers we cover trades at -48% fair-value upside, at -67%, ALUVI screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF €3.79 €4.37 €5.00 80
Rev-Margin DCF €2.82 €3.09 €3.39 74
ROIC Compounder €1.96 €1.99 €2.01 72
All 22 models by family
DCF Models
FCF DCF €3.77 €4.41 €5.16 38
5Y Revenue Exit €2.82 €3.04 €3.28 39
5Y EBITDA Exit €3.43 €4.13 €4.89 41
5Y P/E Exit €2.96 €3.29 €3.60 38
10Y Revenue Exit €3.23 €3.50 €3.78 36
10Y EBITDA Exit €3.57 €4.13 €4.79 37
10Y P/E Exit €3.31 €3.64 €3.99 35
Earnings-Based
Graham-Dodd €0.2900 €0.7000 €0.9000 54
PEG = 1.0 €0.1200 €0.1800 €0.2300 46
EPV €1.96 €1.99 €2.01 59
Multiples
P/E Multiple €0.6600 €0.8800 €1.11 63
P/S Multiple €0.5400 €0.7200 €0.8900 58
P/B Multiple €0.5400 €0.7200 €0.8900 55
EV/EBIT €2.20 €2.36 €2.52 53
EV/EBITDA €3.35 €3.90 €4.45 54
EV/Revenue €2.06 €2.21 €2.36 43
Asset-Based
NCAV (Graham) €2.06 €2.77 €4.13 50
Growth DCF
Growth DCF €3.79 €4.37 €5.00 80
Rev-Margin DCF €2.82 €3.09 €3.39 74
Economic Profit
Residual Income €2.53 €2.25 €1.41 61
ROIC Compounder €1.96 €1.99 €2.01 72
Growth Earnings
Growth-Adj P/E €0.5100 €0.7200 €0.9400 68

Widest divergence: DCF Models (€3.64) versus Earnings-Based (€0.7000). Highest evidence: Growth DCF (80).

Notify me when ALUVI reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) €7.0M
Revenue growth (YoY) +7.4%
Net margin 1.4%
Return on equity 1.0%
Free cash flow €627K FY2022
P/E ratio 62.3
More key figures
Operating margin 2.2%
EPS (TTM) €0.0400
EPS growth (YoY) -15.9%
Net cash €4.1M FY2025

Figures from reported company fundamentals · as of Jul 20, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 64/100

Of which business quality 68 · Market factors (momentum, volatility) 40

Profitability 30
Margins and returns on capital today
Quality Growth 21
Are margins and returns improving?
Cashflow 72
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 90
Disciplined investing over empire-building
Low Volatility 52
Calm price path (market factor)
Momentum 32
Price trend over the last 3–12 months (market factor)
52W Momentum 39
Distance to the 52-week high (market factor)
Net Issuance 100
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

UV Germi SA designs, manufactures, and sells ultraviolet devices for the treatment of air, water, and surfaces in France.

Full company description

UV Germi SA designs, manufactures, and sells ultraviolet devices for the treatment of air, water, and surfaces in France. The company offers its products in the areas of drinking water, seawater, dechloramination, wastewater and industrial process water, private pool, legionella, germiserre, small flow rates, ageing, industrial clean water, and livestock farming industries. It also provides after-sales services, such as installations, online troubleshooting, technical advice, diagnostics, spare parts supplies, on-site intervention, and training on the use of the equipment. The company was founded in 2009 and is headquartered in Saint-Viance, France.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

UV Germi SA reported revenue of €6.8M in FY2025 versus €6.3M in FY2021, a compound +1.9%/yr. Reported net income was €101K in FY2025.

Growth Quality 40/100
Revenue growth is weak, negative or inconsistent.
Latest Revenue (FY 2025)
€6.8M
Latest YoY
−20.1%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
−1.7%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+0.4%
Avg. growth/yr (11Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+6.7%
Revenue +1.9%/yr
FY21 €6.3M
FY22 €7.2M
FY23 €8.0M
FY24 €8.5M
FY25 €6.8M
Net income
FY21 −€870K
FY22 €66.0K
FY23 €290K
FY24 €710K
FY25 €101K

ALUVI screens 67% overvalued. Compare with Veralto Corporation →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "UV Germi SA Fair Value". https://www.fairvalue-calculator.com/stock/ALUVI

Peer Group

Pollution & Treatment Controls · 91 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 64 · Top 25%
Fair Value upside −67% · Bottom 25%
Return on equity (TTM) 1% · Below median
Return on assets 0% · Below median
Net margin (TTM) 1% · Below median
Operating margin (TTM) 2% · Below median
Revenue growth 7% · Above median
Debt / equity 0.02× · Lower than median

Valuation Multiples vs Pollution & Treatment Controls median · lower = cheaper

P/E (TTM) 62.3× · Pricier than 75% of peers
P/B 0.70× · Cheaper than median
P/S (TTM) 0.98× · Cheaper than median
P/FCF 11.0× · Pricier than median
EV/EBITDA 6.1× · Cheaper than 75% of peers

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0 · sector 0
FUTURE 37 · sector 14
PAST 4 · sector 10
HEALTH 99 · sector 95
DIVIDEND 0 · sector 37

VALUE 0: the price sits above our fair-value range.

Insider activity: 30/100

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pollution & Treatment Controls stocks, each showing price versus our Fair Value estimate (as of Jul 20, 2026).

Stock Price Fair Value vs Fair Value
Veralto Corporation VLTO $94.21 $69.11 -27%
Zurn Elkay Water Solutions Corporation ZWS $47.63 $24.92 -48%
Canmax Technologies Co 300390 ¥57.02 ¥10.41 -82%
CECO Environmental Corp CECO $83.63 $15.19 -82%
Fujian Longking Co 600388 ¥17.58 ¥15.59 -11%
Munters Group MTRS kr 166.60 kr 16.90 -90%
China Conch Venture Holdings 0586 HK$8.83 HK$14.14 +60%
Mega Union Technology Inc 6944 1,005 TWD 539.58 TWD -46%
MayAir Technology (China) Co 688376 ¥96.57 ¥18.80 -81%
Shanghai Emperor of Cleaning Hi-Tech Co 603200 ¥38.97 ¥5.73 -85%

Compare UV Germi SA with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Industrials stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is UV Germi SA (ALUVI) overvalued or undervalued?
As of Jul 20, 2026, our model estimates a fair value of €0.8800 versus a price of €2.70, about −67% (overvalued).
What is the fair value of ALUVI?
Our model-based fair value for UV Germi SA is €0.8800 (as of Jul 20, 2026), built from audited fundamentals. The current price is €2.70.
What is the quality score of ALUVI?
UV Germi SA has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of UV Germi SA (ALUVI)?
UV Germi SA reported trailing-twelve-month revenue of about €7.0M (latest available figure, as of Jul 20, 2026).
What is the net profit margin of ALUVI?
The net profit margin of UV Germi SA is about 1.4%, meaning it keeps roughly 1.4% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track UV Germi SA and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.